CG Oncology Inc. (CGON)
NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 62.38 0.00%
CGON stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.53B
- EPS (TTM)
- -$2.69
- Dividend yield
- None
- 52-week range
- 35.80 – 80.97
- Day range
- 61.93 – 63.64
- Volume / Avg
- 621.82K / 899.28K
- Beta
- —
- Shares outstanding
- 88.64M
52-week range
CGON stock today
CG Oncology (CGON) closed at $62.38 on Oct 7, down 1.98% (-$1.26), versus the S&P 500's 0.22% decline. Shares are 23.0% below their 52-week high of $80.97, set on Aug 19, 2026 and 74.2% above the 52-week low of $35.80, in the middle of the past year's range. CGON is up 50.2% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 64.2%.
CG Oncology has posted a net loss over the last twelve months (EPS of -$2.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CG Oncology
Company profileCG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Arthur Kuan
- Headquarters
- Dallas, TX
- Employees
- 142
- IPO year
- 2024
- Website
- cgoncology.com
Financial highlights
Full financialsIn fiscal 2025, CG Oncology generated $4.0 million in revenue, up 254.7% from fiscal 2024, its 2nd consecutive year of revenue growth. CG Oncology reported a net loss of $161.0 million, compared with a loss of $88.0 million a year earlier. Operating margin was -4722.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $4.04M | $1.14M | $204.00K |
| Growth | +254.70% | +458.33% | — |
| Net income | $-161.00M | $-88.04M | $-48.61M |
| EPS (diluted) | $-2.08 | $-1.41 | $-15.65 |
Analyst forecast
ForecastConsensus (15 analysts)
none
Avg. price target
$91.08+46.01%
- Strong buy 4
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-0.90 vs —
CG Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KODKodiak Sciences Inc | 91.08 | -1.36% | $5.72B | vs CGON |
| IOVAIovance Biotherapeutics Inc. | 12.92 | -0.35% | $5.85B | vs CGON |
| SRRKScholar Rock Holding Corporation | 42.20 | -0.59% | $5.14B | vs CGON |
| CRSPCRISPR Therapeutics AG | 52.35 | -3.06% | $5.06B | vs CGON |
| IMVTImmunovant Inc. | 32.04 | -0.22% | $6.62B | vs CGON |
| ADPTAdaptive Biotechnologies Corporation | 26.28 | -2.30% | $4.19B | vs CGON |
| RLAYRelay Therapeutics Inc. | 17.95 | -4.22% | $3.93B | vs CGON |
| TARSTarsus Pharmaceuticals Inc. | 73.61 | -0.67% | $3.44B | vs CGON |
Indexes, lists and sector
CG Oncology stock FAQ
What is CG Oncology's stock price today?
CGON last traded at $62.38 as of Oct 7, 4:00 PM EDT, down 1.98% on the day. Prices are delayed at least 15 minutes.
Who is CG Oncology's CEO?
Mr. Arthur Kuan is the chief executive officer of CG Oncology Inc., which has about 142 employees.
What is the CGON 52-week high?
The 52-week high for CGON is $80.97 and the 52-week low is $35.80. The stock is currently 23.0% below its high.